Peter Rhode - Jan 14, 2022 Form 4 Insider Report for HCW Biologics Inc. (HCWB)

Role
Title of the Officer: Chief Scientific Officer and Vice President of Clinical Operations.
Signature
/s/ Nicole Valdivieso, as Attorney-in-Fact for Peter Rhode
Stock symbol
HCWB
Transactions as of
Jan 14, 2022
Transactions value $
$360
Form type
4
Date filed
1/19/2022, 04:42 PM
Previous filing
Sep 10, 2021
Next filing
Nov 20, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HCWB Common Stock Options Exercise $360 +1.71K +3.66% $0.21* 48.5K Jan 14, 2022 Direct
transaction HCWB Common Stock Options Exercise $0.14 +1 +0% $0.14* 48.5K Jan 14, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HCWB Stock Option Grant (Right to Buy) Options Exercise $0 -1.71K -20% $0.00 6.86K Jan 14, 2022 Common Stock 1.71K $0.21 Direct F1
transaction HCWB Stock Option Grant (Right to Buy) Options Exercise $0 -1 0% $0.00 51.4K Jan 14, 2022 Common Stock 1 $0.14 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 20% of the total shares subject to the stock option grant vested on December 22, 2021; 20% of the total shares subject to the stock option grant will vest on December 22, 2022; 25% of the total shares subject to the stock option grant will vest on December 22, 2023; and 35% of the total shares subject to the stock option grant will vest on December 22, 2024, subject to the reporting person's continuous service through the applicable vesting date.
F2 These option shares were part of a stock option grant covering 85,713 shares of common stock. 20% of the total shares subject to the stock option grant vested on May 30, 2020; 20% of the total shares subject to the stock option grant vested on May 30, 2021; 25% of the total shares subject to the stock option grant will vest on May 30, 2022; and 35% of the total shares subject to the stock option grant will vest on May 30, 2023, subject to the reporting person's continuous service through the applicable vesting date.

Remarks:

Title of the Officer: Chief Scientific Officer and Vice President of Clinical Operations.